Allstate reports Q1 2026 results today — the defining moment for a stock that has been quietly accumulating bearish positioning all month, even as the price itself barely moved.
The clearest sign of unease is in options. The put/call ratio has climbed to 1.23, nearly two standard deviations above its 20-day average of 1.12. That is the most defensive reading the options market has produced for ALL in recent weeks, and it has drifted higher through most of April as the earnings date approached. The 52-week high on the PCR is 1.31, so the current reading is not at an extreme — but the direction of travel is unambiguous.
Short interest tells a related story. Bears have been adding quietly for the past four weeks, lifting short positions by roughly 16% over the month to around 2.8% of the free float. That is not a heavily shorted stock by any measure, and the borrow market remains almost comically relaxed — availability is running above 2,800%, meaning there is no squeeze pressure whatsoever in the lending pool. Cost to borrow is just 0.39% annualised, down nearly 20% over the past month. What this framing tells you is that the recent short-side accumulation is a deliberate directional bet, not a technical artefact of a tight borrow market. Somebody is choosing to add exposure ahead of this print.
The Street is genuinely divided on where ALL goes from here. The bull case rests on improving auto underwriting — policies-in-force growing at roughly 2.8% monthly and reserve developments that have been favourable — while the bear case centres on a combined ratio running noticeably worse than management's long-term 95% target, combined with the risk that competitive pressure erodes pricing power in personal lines. Analyst targets reflect this split starkly: Barclays carries an Underweight with a $208 target (below the current $216.40), while Mizuho Outperform sits at $265 and JPMorgan Overweight is at $263. The mean target of $240 implies around 11% upside, but the dispersion on that number is wide enough to be less useful than usual. Recent analyst activity has been tinkering at the margins rather than signalling conviction — both Wells Fargo and Barclays nudged targets by a single dollar in early April while leaving ratings unchanged.
Valuation gives the bulls something to work with. The trailing P/E has moved up through April, now around 8.4x — cheap on an absolute basis for a large-cap insurer — while EV/EBITDA is near 11.5x. Factor scores support the same read: the company scores in the 87th percentile on EPS surprise history and in the 77th on 90-day EPS momentum, suggesting it has a habit of beating the consensus number when it matters. The short score is a modest 37.9 out of 100 and has risen only gradually this month, consistent with the slow accumulation in SI rather than any sudden squeeze-risk signal.
CEO Tom Wilson sold roughly $5.5 million in stock across a cluster of transactions in mid-March, at prices between $207 and $213. Division president Jesse Merten sold a similar-sized block in late February. Neither trade is individually alarming — scheduled sales by long-tenure executives are common — but the clustering of senior sales just ahead of an earnings cycle is a data point the market will note. Institutional flows from the most recent quarter-end show Vanguard and BlackRock adding modestly while State Street added a more material 438,000 shares. GQG Partners and Putnam also built meaningful new positions in the quarter, providing some demand-side support.
The reaction pattern from recent quarters adds useful context without offering a template. The last two prints produced modest next-day moves of under 1%, while the Q4 2025 release delivered a 6.7% one-day gain. What to watch tonight is less about whether auto underlying margins improved and more about whether management raises or softens language on catastrophe loss assumptions — the variable that has most consistently driven the gap between bull and bear cases.
See the live data behind this article on ORTEX.
Open ALL on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
